Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Christina Stahre
Observed names:
C. A. M. Stahre,
C. I. Stahre,
Stahre, C,
Stahre, Christina
Institution:
AstraZeneca (Sweden)
Observed institution:
AstraZeneca (Sweden)
OpenAlex ID:
A5111493284
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
2016
·
Ofri Mosenzon
, Gil Leibowitz
, et al.
·
Diabetes Care
·
281
Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial
2017
·
Benjamin M. Scirica
, Ofri Mosenzon
, et al.
·
JAMA Cardiology
·
124
PDF
Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
2015
·
Lawrence A. Leiter
, Hwee Teoh
, et al.
·
Diabetes Care
·
88
Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
2015
·
Ofri Mosenzon
, Cheryl Wei
, et al.
·
Diabetes Care
·
73
Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin
2014
·
Itamar Raz
, Deepak L. Bhatt
, et al.
·
Diabetes Care
·
68
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial
2013
·
O. Mosenzon
, I. Raz
, et al.
·
Diabetes/Metabolism Research and Reviews
·
52
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion
2016
·
Faiez Zannad
, Wendy Gattis Stough
, et al.
·
European Heart Journal - Cardiovascular Pharmacotherapy
·
38
PDF
Frequency of cancer events with saxagliptin in the SAVOR‐TIMI 53 trial
2015
·
L. A. Leiter
, H. Teoh
, et al.
·
Diabetes Obesity and Metabolism
·
37
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy
2010
·
Gregory Y.H. Lip
, Lars H. Rasmussen
, et al.
·
Thrombosis Research
·
29
Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)
2021
·
Yasunori Aoki
, Bengt Hamrén
, et al.
·
PLoS ONE
·
20
PDF
Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial
2016
·
Avivit Cahn
, Itamar Raz
, et al.
·
Diabetes Care
·
16
Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials
2017
·
Mikaela Sjöstrand
, Cheryl Wei
, et al.
·
Diabetes Therapy
·
10
PDF
Hypoglycaemia manifestations and recurrent events: L essons from the SAVOR‐TIMI 53 outcome study
2017
·
Avivit Cahn
, Ofri Mosenzon
, et al.
·
Diabetes Obesity and Metabolism
·
7
Abstract 5621: A Phase 2 Feasibility Trial of the Oral Direct Thrombin Inhibitor AZD0837 in the Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation, Who Are Unable or Unwilling to Take Warfarin Therapy
2009
·
Gregory Y Lip
, Lars H Rasmussen
, et al.
·
Circulation
A phase 2 feasibility trial of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolic events in patients with atrial fibrillation, who are unable to unwilling to take warfarin therapy
2009
·
Lip, GY
, Rasmussen, Lars Hvilsted
, et al.
Show more works
View as search
Works count:
17
Citation count:
843
H-index:
11
I10-index:
12
Year
Topic
Type